

# Yannick Vermeiren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3397057/publications.pdf>

Version: 2024-02-01

48  
papers

1,619  
citations

361045

20  
h-index

344852

36  
g-index

61  
all docs

61  
docs citations

61  
times ranked

2338  
citing authors

#	ARTICLE	IF	CITATIONS
1	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. <i>Cortex</i> , 2015, 73, 36-61.	1.1	201
2	Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation. <i>Neuron</i> , 2019, 103, 702-718.e5.	3.8	198
3	Distinct amyloid- $\beta$ and tau-associated microglia profiles in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021, 141, 681-696.	3.9	167
4	Targeting the norepinephrinergetic system in Parkinson's disease and related disorders: The locus coeruleus story. <i>Neurochemistry International</i> , 2017, 102, 22-32.	1.9	95
5	Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2019, 151, 656-668.	2.1	81
6	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2691-2700.	1.5	70
7	Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 947-958.	1.3	58
8	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 819-833.	1.2	53
9	Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 265-275.	1.3	50
10	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. <i>Current Alzheimer Research</i> , 2016, 13, 1145-1164.	0.7	50
11	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 7.	3.0	47
12	A complete pupillometry toolbox for real-time monitoring of locus coeruleus activity in rodents. <i>Nature Protocols</i> , 2020, 15, 2301-2320.	5.5	46
13	The role of serotonin within the microbiota-gut-brain axis in the development of Alzheimer's disease: A narrative review. <i>Ageing Research Reviews</i> , 2022, 75, 101556.	5.0	44
14	Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 763-776.	1.2	39
15	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 797-819.	1.2	38
16	Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. <i>Alzheimer's and Dementia</i> , 2013, 9, 488-498.	0.4	37
17	Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue. <i>Journal of Chromatography A</i> , 2014, 1353, 28-39.	1.8	36
18	Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1079-1096.	1.2	33

#	ARTICLE	IF	CITATIONS
19	Serum MHPG Strongly Predicts Conversion to Alzheimer's Disease in Behaviorally Characterized Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 871-891.	1.2	32
20	Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes. <i>Frontiers in Neuroscience</i> , 2018, 12, 185.	1.4	32
21	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 25.	2.4	23
22	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers. <i>Brain</i> , 2022, 145, 4056-4064.	3.7	19
23	Serum NGAL is Associated with Distinct Plasma Amyloid- $\beta^2$ Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 733-743.	1.2	17
24	Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 172-181.	1.2	16
25	Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. <i>Neurobiology of Disease</i> , 2017, 105, 235-244.	2.1	14
26	Sampling issues of cerebrospinal fluid and plasma monoamines: Investigation of the circadian rhythm and rostrocaudal concentration gradient. <i>Neurochemistry International</i> , 2019, 128, 154-162.	1.9	14
27	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 108, 99-109.	1.5	13
28	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 71-84.	1.5	12
29	Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum. <i>Neurochemical Research</i> , 2020, 45, 1191-1201.	1.6	12
30	5-HT7 receptors in Alzheimer's disease. <i>Neurochemistry International</i> , 2021, 150, 105185.	1.9	12
31	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 99-111.	1.2	9
32	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2019, 497, 204-211.	0.5	9
33	iPSC-derived cortical neurons to study sporadic Alzheimer disease: A transcriptome comparison with post-mortem brain samples. <i>Toxicology Letters</i> , 2022, 356, 89-99.	0.4	8
34	Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective. <i>Frontiers in Neurology</i> , 2020, 11, 595.	1.1	7
35	Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 313-324.	0.9	5
36	Serum Glutamine Synthetase Has No Value as a Diagnostic Biomarker for Alzheimer's Disease. <i>Neurochemical Research</i> , 2011, 36, 1858-1862.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Chronic adolescent stress increases exploratory behavior but does not appear to change the acute stress response in adult male C57BL/6 mice. <i>Neurobiology of Stress</i> , 2021, 15, 100388.	1.9	3
38	Psychiatric Disorders in Dementia. , 2014, , 271-324.		1
39	Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer's Disease but Are Not Correlated with Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 693-704.	1.2	1
40	Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
41	Plasma 5-HIAA activity indicative of serotonergic disturbances in cognitively impaired, elderly patients experiencing postoperative delirium. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	1
42	P1-112: MONOAMINERGIC BRAIN TOPOCHEMISTRY IN ALZHEIMER'S DISEASE VERSUS HEALTHY ELDERLY. , 2014, 10, P342-P342.		0
43	P2-148: MONOAMINERGIC NEUROTRANSMITTER LEVELS IN POST-MORTEM BRAIN REGIONS OF PATIENTS WITH LEWY BODY AND ALZHEIMER'S DEMENTIA: ASSOCIATION WITH DEPRESSION AND PSYCHOSIS. , 2014, 10, P526-P526.		0
44	[P4-405]: MONOAMINERGIC CORRELATES OF DISINHIBITED BEHAVIOURS IN THE NOVEL TAU58/4 TRANSGENIC MOUSE MODEL FOR TAUOPATHY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1486.	0.4	0
45	[P4-473]: BIOLOGICAL FLUID MONOAMINE LEVELS TO EXPLORE THE NEUROCHEMICAL CONTINUUM BETWEEN FRONTOTEMPORAL DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1514.	0.4	0
46	P2-228: PREANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P755.	0.4	0
47	ABCA7 PTC mutation carriers present with Alzheimer's disease pathology and cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e041513.	0.4	0
48	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0